top of page

Originally spun out of the MIT Department of Chemistry in 2013, C2Sense develops advanced optical sensing systems that provide unprecedented sensitivity and specificity at extremely low cost.

 

In the medical space, C2Sense’s “Halo” platform uses fluorescence to convert conventional lateral flow assays into highly sensitive and machine-readable diagnostic tests.

 

In supply chains, C2Sense applies its expertise in chemistry and optics to create revolutionary anti-counterfeiting and sensing solutions.

Our Story

Headquartered in Watertown, Massachusetts, the Halo team features 14 scientists, engineers, and business leaders designing and implementing innovative solutions with the goal of dependable and accessible diagnostics for all people.  

Our Team

Halo® in the News

April 25, 2023 - C2Sense, Inc., today announced that its Board of Directors has appointed Jim Mahoney, MBA, MMA as an independent director effective January 31, 2023. 

March 30, 2023 - C2Sense, Inc.,  announced the appointment of Adam Behrens, Ph.D., to its Board of Directors as an independent director effective January 31, 2023. 

March 8, 2023 – C2Sense, Inc., today announced the appointment of the Honorable Andrew Weber to its Board of Directors effective January 31, 2023.

February 1, 2023 - Digital innovation and connected diagnostics can help address global health disparities, but it is essential to ensure health governance advances alongside new technologies.

January 4, 2023 - C2Sense, Inc. announced today the successful second closing of its $8M Series B financing round with participation from new and existing investors.

August 25, 2022 - C2Sense, Inc., is a technology company developing a suite of diagnostic products for healthcare, wellness and safety.

April 18, 2022- C2Sense, Inc. has published a proof-of-concept study in Frontiers in Public Health demonstrating the sensitivity and specificity of its Halo technology platform to detect SARS-CoV-2.

bottom of page